Estimates Revisions Keros Therapeutics, Inc.
Stocks
KROS
US4923271013
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
17:05:38 20/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 10.58 USD | -4.68% |
|
-0.75% | -48.04% |
| 08-11 | BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20 | MT |
| 08-03 | Keros Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
- Stock Market
- Stocks
- KROS Stock
- Consensus Keros Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
